Bacterial strains, plasmids, materials, and instrumentation: Chemically competent E. coli TOP10 and BL21 (DE3) were bought from Invitrogen. Restriction endonucleases, T4 DNA ligase, and Phusion DNA polymerase were purchased from NEB.
pAAC(3)-IV-pET23a (a gift from Dr. John S. Blanchard, Albert Einstein College of Medicine, NY). The primers used for the amplification of each gene are listed in Table   S1 . The amplified genes were inserted into the linearized pET28a, pET22b, and IntpET19b-pps vectors via the corresponding NdeI/XhoI (pAAC(6')-APH(2")-pET28a-(NHis), pAAC(6')-APH(2")-pET22b(CHis), and pAAC(6')-APH(2")-Int-pET19b-pps-(NHis)), NdeI/HindIII (pAAC(3)-IV-pET28a(NHis)), and NdeI/BamHI (pAAC(3)-IV-IntpET19b-pps(NHis)) restriction sites, to afford constructs that encode for NHis-tagged and CHis-tagged proteins. The Int-pET19b-pps vector was utilized to produce proteins with an easily cleavable NHis-tag by use of precision protease. Expression of AAC(6')-APH(2")-pET28a(NHis), AAC(6')-APH(2")-pET22b(CHis), AAC(6')-APH(2")-Int-pET19b-pps(NHis), AAC(3)-IV-pET28a(NHis), and AAC(3)-IV-Int-pET19b-pps-(NHis) was done following transformation into E. coli TOP10 competent cells. The plasmids were sequenced (The University of Michigan DNA Sequencing Core) and showed perfect alignment with the reported sequences (PubMed accession number NC_002774 for AAC(6')-APH(2") and PubMed accession number DQ241380 for
AAC(3)-IV).

Overproduction and Purification of AAC(6')-APH(2")(NHis), AAC(6')-APH(2")-(CHis), and AAC(3)-IV(NHis).
Purified plasmids AAC(6')-APH(2")-pET28a(NHis), AAC(6')-APH(2")-pET22b(CHis), AAC(6')-APH(2")-Int-pET19b-pps(NHis), AAC(3)-IVpET28a(NHis), and AAC(3)-IV-Int-pET19b-pps(NHis) were transformed into E. coli BL21 (DE3) competent cells for protein expression and purification. 1 L of Luria-Bertani (LB) medium supplemented with kanamycin (50 µg/mL) (for pET28a constructs) or ampicillin (100 µg/mL) (for pET22b and Int-pET19b-pps constructs) were inoculated with 10 mL of an overnight culture of the transformants harboring the AAC(6')-
AAC(3)-IV-pET28a, and AAC(3)-IV-Int-pET19b-pps constructs and incubated at 37
°C. The cultures were grown to an OD 600 of ~0.6, induced with 1 mL of a 1 M stock of isopropryl-β-thiogalactopyranoside (IPTG) (final concentration of 1.0 mM) and shaken for an additional 4 h at 37 °C. Cells were harvested by centrifugation (6000 rpm, 10 min, 4 °C, Beckman Coulter Aventi JE centrifuge, F10 rotor) and resuspended in buffer A [300 mM NaCl and 50 mM Na 2 HPO 4 pH 8.0 adjusted at RT, (containing 10%   Table S1 . Primers used for the PCR amplification of the AAC(6')-APH(2") gene from S. ) [2] due to the formation of 4-thiopyridone, using acetyl-CoA (40 µM), DTDP (2 mM), and aminoglycoside (20 µM) in the various buffers (50 mM). A pH range from 4.5 to 9.0 using 0.3 increments was used to determine the optimum pH of the AACs activity with individual sugars. Citrate-phosphate buffer (50 mM) was used for pHs 4.5 to 5.4, MES (50 mM) was used for pHs 5.7 to 6.6, HEPES (50 mM) for pHs 6.9 to 7.8, and Tris ( The R f values observed were 0.46 for 6',3-N-diacetyl-neomycin B.
BioTLC. Reactions (10-20 µL) were inspired by the work of Ostash et al. [3] and were carried out in MES (50 mM, pH 6.6 adjusted at RT) for AAC(6')-APH (2" kanamycin A with AAC(6')-APH(2")(NHis) (pET28a) and acetyl-CoA, F. kanamycin A with AAC(6')-APH(2")(NHis) (pET28a) and n-propionyl-CoA, G. kanamycin A with AAC(6')-APH(2")(no tag) (Int-pET19b-pps) and acetyl-CoA, H. kanamycin A with AAC(6')-APH(2")(no tag) (Int-pET19b-pps) and n-propionyl-CoA, I. neomycin B with AAC(6')-APH(2")(CHis) (pET22b) and acetyl-CoA, and J. neomycin B with AAC(6')-APH(2")(CHis) (pET22b) and npropionyl-CoA. Figure S12 . Example kinetic initial rates of A. amikacin with AAC(6')-APH(2")(CHis) (pET22b) and acetyl-CoA, B. amikacin with AAC(6')-APH(2")(CHis) (pET22b) and n-propionyl-CoA, C. amikacin with AAC(6')-APH(2")(CHis) (pET22b) and malonyl-CoA, D. gentamycin with AAC(6')-APH(2")(CHis) (pET22b) and acetyl-CoA, E. gentamicin with AAC(6')-APH(2")(CHis) (pET22b) and n-propionyl-CoA, F. gentamicin with AAC(6')-APH(2")(CHis) (pET22b) and malonyl-CoA, G. sisomicin with AAC(6')-APH(2")(CHis) (pET22b) and acetylCoA, H. sisomicin with AAC(6')-APH(2")(CHis) (pET22b) and n-propionyl-CoA, I. tobramycin with AAC(6')-APH(2")(CHis) (pET22b) and acetyl-CoA, and J. tobramycin with AAC(6')-APH(2")(CHis) (pET22b) and n-propionyl-CoA. 
